Tag: ATB-346

January 21, 2019

Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics (TSXV:ATE,OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has...
November 28, 2018

Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation,...
August 29, 2018

Antibe Therapeutics Reports Full Phase 2B ATB-346 Trial Results

The trial, which originally finished in March 2018, shows that ATB-346 met the primary endpoint of reduced ulceration rate.
August 29, 2018

Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346

Antibe Therapeutics (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it...
July 3, 2018

Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346

Antibe Therapeutics (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the secondary...
May 22, 2018

Antibe Therapeutics Looking for More Licensing Deals

Antibe Therapeutics is trying to change the game of non-steroidal anti-inflammatory drugs (NSAID)—the “largest category of drugs globally,” CEO Dan...
January 21, 2016

Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce...